Live Breaking News & Updates on Dexamethasone

Stay informed with the latest breaking news from Dexamethasone on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Dexamethasone and stay connected to the pulse of your community

National News: Two hundred Omicron cases reported in India so far, 5,326 new COVID-19 cases

Two hundred Omicron cases reported in India so far, 5,326 new COVID-19 cases : Rashtra News #Omicron #cases #reported #India #COVID19 #cases Two hundred cases of Omicron variant of coronavirus have been detected in India so far out of which 77 patients have recovered or migrated, the Union Health Ministry said on December 21. Maharashtra

India , Kerala , Delhi , Karnataka , Telangana , Andhra-pradesh , Union-health-ministry , Astrazeneca , B-1-529 , B-1-7 , Bed-availability

Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

Experts discuss their institution’s implementation of step-up dosing for bispecific antibodies and share their best practices.

Matthew-pianko , Anthony-perissinotti , Ryan-haumschild , Interesting-american-society-of-hematologyabstracts , Practice-pearls , American-society , Pharmacy-times , Step-up-dosing , Bispecific-antibodies , Myeloma , Outpatient , Infrastructure

ASH 2023: Analyzing IsKia Trial

The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.

Conference-perspectives , Multiple-myeloma , Analyzing-iskia , American-society-of-hematology , Ash , Newly-diagnosed-multiple-myeloma , Triplet-therapy , Quadruplet-therapy , Perseus-trial , Daratumumab , Bortezomib

Treatment of Multiple Myeloma at Early Relapse

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

Multiple-myeloma , Mm , Early-relapse , Relapsed-refractory-mm , Rrmm , Mm-treatment , Daratumumab , Carfilzomib , Pomalidomide , Dexamethasone , Dkd

The Evolving Treatment Paradigm for Transplant Ineligible MM

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Multiple-myeloma , Evolving-treatment-paradigm , Transplant-ineligible , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , Daratumumab , Lenalidomide , Dexamethasone

Highlights from ASH 2023 in Transplant-Eligible NDMM

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

Multiple-myeloma , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , Perseus , Griffin-trial , Perseus-trial , Daratumumab , Lenalidomide

Advances in the Treatment of High-Risk MM

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Multiple-myeloma , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , High-risk , Standard-risk , Iskia , Isatuximab , Carfilzomib

Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, MD, PhD, presents results from the phase III randomized IsKia trial investigating isatuximab-carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in patients with newly diagnosed multiple myeloma.

California , United-states , San-diego , Iskia-trial , Pre-transplant-induction , Post-transplant-consolidation , Newly-diagnosed-multiple-myeloma , Multiple-myeloma , Iskia , Iskia-study , Isatuximab

#VisualAbstract: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Minute-medicine-inc , Bortezonib , Daratumumab , Dexamethasone , Lenalomide , Multiple-myeloma , Vrd , Studygraphics ,

Dexamethasone does not improve tuberculous meningitis survival in HIV

1. In this randomized controlled trial, compared to placebo, dexamethasone did not improve survival in people living with human immunodeficiency virus (PLWH) as well as tuberculous meningitis. 2. The incidence of adverse events and inflammatory syndrome was similar between the dexamethasone and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Tuberculous meningitis is a

Vietnam , Republic-of , Indonesia , Minute-medicine-inc , Rating-level , Chronic-disease , Dexamethasone , Hiv , Infectious-disease , Meningitis , Public-health